Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of baricitinib versus placebo when added to standard of care which included corticosteroids (86% of the patients) in patients hospitalized with COVID-19 requiring invasive mechanical ventilation or ECMO at baseline

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of baricitinib versus placebo when added to standard of care which included corticosteroids (86% of the patients) in patients hospitalized with COVID-19 requiring invasive mechanical ventilation or ECMO at baseline

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 10 Aug 2021 New trial record
    • 03 Aug 2021 According to an Eli Lilly and Company media release, these new data from the COV-BARRIER sub-study will also be shared with regulatory authorities in the U.S., European Union and other geographies.
    • 03 Aug 2021 According to an Eli Lilly and Company media release, company intends to publish detailed results from this additional sub-study in a peer-reviewed journal and present the findings at a medical meeting in the coming months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top